Brazil covid-19 death infection patient Brazil

COVID-19 Scan for Jul 23, 2020

www.cidrap.umn.edu

Brazilian trial finds no COVID-19 benefit from hydroxychloroquine, azithromycinA randomized controlled trial of hospitalized COVID-19 patients in Brazil found that the use of hydroxychloroquine, with or without azithromycin, did not improve clinical status at 15 days compared with standard care, researchers reported today in the New England Journal of Medicine.The multicenter trial, conducted at 55 hospitals in Brazil, included 667 patients with suspected or confirmed COVID-19 and mild-to-moderate illness.

Participants were randomly assigned 1:1:1 to receive standard of care, standard of care plus 400 milligrams of hydroxychloroquine twice daily, or standard of care plus hydroxychloroquine and azithromycin (500 mg once daily for 7 days).Sta

The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News